Data presented today at the EuroPCR 2022 event supported the use of the Medtronic (NYSE:MDT) Resolute Onyx drug-eluting stent. University of Padua Medical School Head of Interventional Cardiology Dr. Giuseppe Tarantini presented late-breaking clinical trial results from the investigator-initiated, Medtronic-funded ROLEX (Revascularization Of … [Read more...] about Medtronic’s Resolute Onyx drug-eluting stent demonstrates strong safety, efficacy
FDA approves Medtronic’s Onyx Frontier drug-eluting coronary stent
Medtronic (NYSE:MDT) announced today that it received FDA approval for its Onyx Frontier drug-eluting stent (DES). Onyx Frontier, the latest iteration of Medtronic’s Resolute DES family, was designed to leverage the same stent platform as Resolute with an enhanced delivery system for improving deliverability and increasing acute performance, … [Read more...] about FDA approves Medtronic’s Onyx Frontier drug-eluting coronary stent
Abbott announces availability of Xience Skypoint drug-eluting stent in extended sizes
Abbott (NYSE:ABT) announced today that its Xience Skypoint drug-eluting stent platform is now available globally. Xience Skypoint has received FDA approval, CE mark and PMDA approval in Japan for the broadest expansion with the availability of extended sizes of 4.5 mm and 5 mm offerings. Get the full story at our sister site, Drug Delivery … [Read more...] about Abbott announces availability of Xience Skypoint drug-eluting stent in extended sizes
ICU Medical beats The Street in Q1
ICU Medical (Nasdaq:ICUI) reported first-quarter results that came in ahead of the consensus earnings per share forecast. The San Clemente, California-based company posted losses of $38.1 million, or $1.61 per share, on sales of $543.1 million for the three months ended March 31, 2022, for a bottom-line slide into the red on sales growth of … [Read more...] about ICU Medical beats The Street in Q1
Avanos rises as Q1 earnings match Wall Street projections
Avanos Medical (NYSE:AVNS) shares ticked up today on first-quarter results that just about matched the consensus forecast. The Alpharetta, Georgia–based pain management and chronic care device company posted profits of $5.8 million, or 12¢ per share, on sales of $197.4 million for the three months ended March 31, 2022, for a bottom-line gain … [Read more...] about Avanos rises as Q1 earnings match Wall Street projections
Study demonstrates freedom from AFib symptoms with use of Abbott’s ablation catheter
Abbott (NYSE:ABT) announced today that a study showed its TactiCath ablation catheter often led to more than a year of freedom from AFib symptoms. The Persist-End study showed that 89% of patients treated for persistent AFib with the company’s TactiCath contact force ablation catheter, Sensor Enabled (TactiCath SE), remained symptom-free for up … [Read more...] about Study demonstrates freedom from AFib symptoms with use of Abbott’s ablation catheter
Abbott announces U.S. launch of Amplatzer steerable delivery sheath for Amulet device
Abbott (NYSE:ABT) announced today that it made the Amplatzer steerable delivery sheath commercially available in the U.S. The Amplatzer steerable delivery sheath works with the Amplatzer Amulet left atrial appendage (LAA) occluder to treat people with AFib who are at risk of ischemic stroke According to a news release, the Amulet with … [Read more...] about Abbott announces U.S. launch of Amplatzer steerable delivery sheath for Amulet device
Recall of Medtronic’s Harmony delivery catheter is Class I
The FDA today announced a Class I recall — the most serious kind — for the Medtronic (NYSE:MDT) Harmony delivery catheter system. Medtronic designed the Harmony transcatheter pulmonary valve (TPV) system for treating a leaky native or surgically repaired right ventricular outflow tract (RVOT). It consists of a transcatheter pulmonary valve and a … [Read more...] about Recall of Medtronic’s Harmony delivery catheter is Class I
Federal Circuit deals Abbott’s St. Jude Medical a setback in catheter IP case
A Federal Circuit court ruled that Abbott (NYSE:ABT) subsidiary St. Jude Medical must face patent infringement claims. Just over one year ago, Abbott’s St. Jude — acquired for $25 billion in 2017 — won a patent dispute over the method for using a double catheter in heart failure patients. Get the full story at our sister site, MassDevice. … [Read more...] about Federal Circuit deals Abbott’s St. Jude Medical a setback in catheter IP case
LimFlow raises $40M for chronic limb-threatening ischemia treatment
LimFlow announced that it closed an oversubscribed Series D financing round worth $40 million (€36 million). Paris-based LimFlow developed the LimFlow system for minimally invasive treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD). The system uses a family of transcatheter products designed … [Read more...] about LimFlow raises $40M for chronic limb-threatening ischemia treatment
